Abstract

Streptomyces are widely used for the production of secondary metabolites with diverse biological activities, including antibiotics. The necessity of alternative antimicrobial agents against multidrug-resistant pathogens is indispensable. However, the production of new therapeutics is delayed in recent days. Thus, the isolation of new Streptomyces species has drawn attention. Nepal—a country rich in biodiversity—has got high possibilities for the discovery of members of actinomycetes, especially in the higher altitudes. However, in vain, only a few screening research works have been reported from Nepal to date. Streptomyces species were isolated on ISP4 media, and characterization was performed according to morphological similarity and 16S rRNA sequence similarity using bioinformatic tools. Ethyl acetate extracts of Streptomyces species were prepared, and the antimicrobial activity was carried out using agar well diffusion technique. In this report, 18 Streptomyces species isolated from the soil were reported based on sequence analysis of 16S rRNA. Among them, 12 isolates have shown antibacterial activity against extended-spectrum beta-lactamase- (ESBL-) producing Escherichia coli. Here, we have also analyzed 16S rRNA in 27 Streptomyces species whose whole-genome sequence is available, which has revealed that some species have multiple copies of the 16S gene (∼1.5 kb) with significant variation in nucleotides. In contrast, some Streptomyces species shared identical DNA sequences in multiple copies of 16S rRNA. The sequencing of numerous copies of 16S rRNA is not necessary, and the molecular sequencing of this region is not sufficient for the identification of bacterial species. The Streptomyces species-derived ethyl acetate extracts from Nepalese soil demonstrate potential activity against ESBL-producing E. coli. Thus, they are potential candidates for antibiotics manufacturing in the future.

Highlights

  • Multidrug-resistant pathogens have drawn global attention as a significant challenge to treat and prevent the growing number of infectious diseases [1, 2]

  • Streptomyces genome contains more than 20 gene clusters to secondary metabolites of higher clinical importance, including antibiotics that could tackle the rise of antimicrobial resistance [8]

  • Many studies report that Streptomyces have tremendous potential to yield secondary metabolites, including anticancer drugs, antibiotics, growth factors, and herbicides [13]. e higher percentage of GC content (∼70%) is present in Streptomyces spp. e 16S rDNA analyses and DNA-DNA hybridization are significant distinguishing properties that separate Streptomyces from other actinobacteria

Read more

Summary

Introduction

Multidrug-resistant pathogens have drawn global attention as a significant challenge to treat and prevent the growing number of infectious diseases [1, 2]. Such resistance typically occurs as a result of drug inactivation, target alteration, and reduced accumulation unsettled to decreased permeability and/or increased efflux [3]. Extended-spectrum beta-lactamases (ESBLs) produced primarily by the bacteria Escherichia coli and Klebsiella pneumoniae confer resistance to most beta-lactam antibiotics, including penicillins and cephalosporins Infections caused by these bacteria are being difficult to treat globally, and the mortality rate has sharply increased along with prolonged hospital stay and greater economic burden [18]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call